The renal denervation product developer secured more than $20m in a round that included strategic investor BrosMed Medical.
Vascular intervention technology provider BrosMed Medical took part in a series B-plus round for Brattea, a China-based developer of renal denervation (RDN) medical technology, on Tuesday sized at over $20m. Healthcare-focused private equity fund Kuanping Capital led the round, which also featured Hengxu Capital, Pudong Science & Technology Investment, Northern Light Venture Capital, BioTrack Capital…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.